Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S]

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S]

Atherosclerosis-related CVD causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocuma...

Full description

Bibliographic Details
Main Authors: Marianne G. Pouwer, Elsbet J. Pieterman, Nicole Worms, Nanda Keijzer, J. Wouter Jukema, Jesper Gromada, Viktoria Gusarova, Hans M.G. Princen
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Journal of Lipid Research
Subjects:
atherosclerosis
drug therapy/hypolipidemic drugs
macrophages/monocytes
apolipoproteins
antibodies
regression
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520435205

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520435205

Similar Items